不同剂量紫杉醇联合顺铂新辅助化疗局部晚期宫颈癌的疗效观察

Effect Analysis of Different Dose Paclitaxel Combined with Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

目的探究与分析不同剂量紫杉醇联合顺铂新辅助化疗局部晚期宫颈癌的临床疗效。方法选取我院收治的100例局部晚期宫颈癌患者,采取随机数字表法将其分成A、B两组,每组50例。A组患者采用紫杉醇135 mg/m2,顺铂60mg/m2,化疗1～2个疗程,化疗时间间隔为21 d,B组患者采用紫杉醇60 mg/m2,顺铂60 mg/m2,化疗1～2个疗程,化疗时间间隔为10 d,两组患者均在化疗结束后行宫颈癌根治术,观察与比较两组患者经不同治疗方法后的临床疗效及不良反应等情况。结果 A、B两组患者经不同用药方式后,肿瘤完全缓解、部分缓解、稳定无变化、进展的人数无明显差异(P>0.05)。A组患者出现严重骨髓抑制的人数明显高于B组患者(P<0.05)。A、B两组患者出现消化道症状、脱发及神经毒性的人数无明显差异(P>0.05)。结论 B组患者所采用的用药方式在辅助化疗局部晚期宫颈癌方面的临床作用显著,且不良反应较少,安全性高,值得在临床上广泛推广应用。

Objective To explore and analyze different doses of paclitaxel and cisplatin neoadjuvant chemotherapy for locally ad- vanced cervical cancer clinical efficacy. Methods Select this hospital treated 100 patients with locally advanced cervical cancer pa- tients, take a random number table wil be divided into A, B groups, each group 50 cases. A group of patients with paclitaxel 135 mg/ m2, cisplatin 60 mg/m2 1 to 2 courses of chemotherapy, chemotherapy interval 21 d B patients with paclitaxel 60 mg/m2, cisplatin 60 mg/m^2, 1 to 2 courses of chemotherapy, chemotherapy interval 10 d, the two groups of patients are at the end of chemotherapy under- went cervical cancer radical surgery, observed with the two groups were compared by the different treatment methods of clinical efficacy and adverse circumstances. Results A, B groups of patients after different mode of administration ,tumor comp｜etc remission, partial re- mission, stable unchanged, the number of progress was no significant difference （ P 〉 0.05 ）. A group of patients with severe bone mar- row suppression was significantly higher than in the number of patients in group B （ P 〈 0.05 ）. No significant difference （ P 〉 0.05 ） in the number of A, B two groups of patients with gastrointestinal symptoms, alopecia and neurotoxicity. Conclusion The mode of ad- ministration used in the B group of patients in the clinical role of adjuvant chemotherapy for locally advanced cervical cancer signifi- cantly fewer adverse reactions, safe, worthy to be widely used in clinical practice.